Диссертация (1140781), страница 19
Текст из файла (страница 19)
Y., Manolis A., McMurray J., Ponikowski P., RosenhekR., Ruschitzka F., Savelieva I., Sharma S., Suwalski P., Tamargo J. L., Taylor C. J., VanGelder I. C., Voors A. A., Windecker S., Zamorano J. L., Zeppenfeld K., Members: A.T. F., Reviewers: D. 2016 ESC Guidelines for the management of atrial fibrillation123developed in collaboration with EACTS: The Task Force for the management of atrialfibrillation of the European Society of Cardiology (ESC)Developed with the specialcontribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed bythe European Stroke Organisation (ESO) // Eur J Cardiothorac Surg.
‒2016.10.1093/ejcts/ezw313.95. Kooiman J., van der Hulle T., Maas H., Wiebe S., Formella S., Clemens A., van BurenM., Janssen M., Rabelink T. J., Huisman M. V. Pharmacokinetics and Pharmacodynamicsof Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease // J Am CollCardiol. ‒ 2016. ‒ T. 67, № 20. ‒ C. 2442-2444.96. Kubitza D., Becka M., Mueck W., Halabi A., Maatouk H., Klause N., Lufft V., WandD. D., Philipp T., Bruck H. Effects of renal impairment on the pharmacokinetics,pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor // Br JClin Pharmacol.
‒ 2010. ‒ T. 70, № 5. ‒ C. 703-12.97. Lau Y. C., Proietti M., Guiducci E., Blann A. D., Lip G. Y. H. Atrial Fibrillation andThromboembolism in Patients With Chronic Kidney Disease // J Am Coll Cardiol. ‒2016. ‒ T. 68, № 13. ‒ C. 1452-1464.98. Lehr T., Haertter S., Liesenfeld K. H., Staab A., Clemens A., Reilly P. A., FriedmanJ. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: doseidentification using pharmacokinetic modeling and simulation // J Clin Pharmacol.
‒2012. ‒ T. 52, № 9. ‒ C. 1373-8.99. Levey A. S., Stevens L. A., Schmid C. H., Zhang Y. L., Castro A. F., Feldman H. I.,Kusek J. W., Eggers P., Van Lente F., Greene T., Coresh J., Collaboration) C.-E. C. K.D. E. A new equation to estimate glomerular filtration rate // Ann Intern Med. ‒ 2009. ‒T. 150, № 9. ‒ C. 604-12.100.
Limdi N. A., Limdi M. A., Cavallari L., Anderson A. M., Crowley M. R., Baird M.F., Allon M., Beasley T. M. Warfarin dosing in patients with impaired kidney function //Am J Kidney Dis. ‒ 2010. ‒ T. 56, № 5. ‒ C. 823-31.124101. Limdi N. A., Beasley T. M., Baird M. F., Goldstein J. A., McGwin G., Arnett D. K.,Acton R.
T., Allon M. Kidney function influences warfarin responsiveness andhemorrhagic complications // J Am Soc Nephrol. ‒ 2009. ‒ T. 20, № 4. ‒ C. 912-21.102. Lindner S. M., Fordyce C. B., Hellkamp A. S., Lokhnygina Y., Piccini J. P.,Breithardt G., Mahaffey K.
W., Singer D. E., Hacke W., Halperin J. L., Hankey G. J.,Berkowitz S. D., Nessel C. C., Becker R. C., Fox K. A., Patel M. R., Investigators R. A.S. C. a. Treatment Consistency Across Levels of Baseline Renal Function WithRivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct FactorXa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke andEmbolism Trial in Atrial Fibrillation) Analysis // Circulation. ‒ 2017. ‒ T. 135, № 10. ‒C.
1001-1003.103. MacIntyre C., Lakdawala N. K. Management of Atrial Fibrillation in HypertrophicCardiomyopathy // Circulation. ‒ 2016. ‒ T. 133, № 19. ‒ C. 1901-5.104. Majeed A., Hwang H. G., Connolly S. J., Eikelboom J. W., Ezekowitz M. D.,Wallentin L., Brueckmann M., Fraessdorf M., Yusuf S., Schulman S.
Management andoutcomes of major bleeding during treatment with dabigatran or warfarin // Circulation.‒ 2013. ‒ T. 128, № 21. ‒ C. 2325-32.105. Manzano-Fernández S., Cambronero F., Caro-Martínez C., Hurtado-Martínez J. A.,Marín F., Pastor-Pérez F. J., Mateo-Martínez A., Sánchez-Martínez M., Pinar-BermúdezE., Valdés M. Mild kidney disease as a risk factor for major bleeding in patients withatrial fibrillation undergoing percutaneous coronary stenting // Thromb Haemost. ‒ 2012.‒ T. 107, № 1.
‒ C. 51-8.106. Marcos E. G., Geelhoed B., Van Der Harst P., Bakker S. J. L., Gansevoort R. T.,Hillege H. L., Van Gelder I. C., Rienstra M. Relation of renal dysfunction with incidentatrial fibrillation and cardiovascular morbidity and mortality: The PREVEND study //Europace. ‒ 2017. ‒ T. 19, № 12. ‒ C. 1930-1936.107. Marijon E., Le Heuzey J. Y., Connolly S., Yang S., Pogue J., Brueckmann M.,Eikelboom J., Themeles E., Ezekowitz M., Wallentin L., Yusuf S., Investigators R.-L.125Causes of death and influencing factors in patients with atrial fibrillation: a competingrisk analysis from the randomized evaluation of long-term anticoagulant therapy study //Circulation.
‒ 2013. ‒ T. 128, № 20. ‒ C. 2192-201.108. Marini C., De Santis F., Sacco S., Russo T., Olivieri L., Totaro R., Carolei A.Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: resultsfrom a population-based study // Stroke. ‒ 2005. ‒ T. 36, № 6. ‒ C. 1115-9.109. Marinigh R., Lane D. A., Lip G. Y. Severe renal impairment and stroke preventionin atrial fibrillation: implications for thromboprophylaxis and bleeding risk // J Am CollCardiol.
‒ 2011. ‒ T. 57, № 12. ‒ C. 1339-48.110. Matsushita K., Ballew S. H., Coresh J. Cardiovascular risk prediction in people withchronic kidney disease // Curr Opin Nephrol Hypertens. ‒ 2016. ‒ T. 25, № 6. ‒ C. 518523.111. Matsushita K., Selvin E., Bash L. D., Astor B. C., Coresh J. Risk implications of thenew CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRDStudy equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC)Study // Am J Kidney Dis. ‒ 2010. ‒ T. 55, № 4.
‒ C. 648-59.112. Matsushita K., van der Velde M., Astor B. C., Woodward M., Levey A. S., de JongP. E., Coresh J., Gansevoort R. T., Consortium C. K. D. P. Association of estimatedglomerular filtration rate and albuminuria with all-cause and cardiovascular mortality ingeneral population cohorts: a collaborative meta-analysis // Lancet. ‒ 2010. ‒ T. 375, №9731. ‒ C. 2073-81.113. Mavrakanas T. A., Samer C. F., Nessim S. J., Frisch G., Lipman M. L.
ApixabanPharmacokinetics at Steady State in Hemodialysis Patients // J Am Soc Nephrol. ‒ 2017.‒ T. 28, № 7. ‒ C. 2241-2248.114. McAlister F., Wiebe N., Jun M., Sandhu R., James M., McMurtry M., HemmelgarnB., Tonelli M. Are Existing Risk Scores for Nonvalvular Atrial Fibrillation Useful forPrediction or Risk Adjustment in Patients With Chronic Kidney Disease? // CanadianJournal of Cardiology. ‒ 2017. ‒ T.
33. ‒ C. 243 - 252.126115. Mozaffarian D., Benjamin E. J., Go A. S., Arnett D. K., Blaha M. J., Cushman M.,Das S. R., de Ferranti S., Després J. P., Fullerton H. J., Howard V. J., Huffman M. D.,Isasi C. R., Jiménez M. C., Judd S. E., Kissela B. M., Lichtman J.
H., Lisabeth L. D., LiuS., Mackey R. H., Magid D. J., McGuire D. K., Mohler E. R., Moy C. S., Muntner P.,Mussolino M. E., Nasir K., Neumar R. W., Nichol G., Palaniappan L., Pandey D. K.,Reeves M. J., Rodriguez C. J., Rosamond W., Sorlie P. D., Stein J., Towfighi A., TuranT. N., Virani S. S., Woo D., Yeh R. W., Turner M. B., Members W. G., Committee A. H.A. S., Subcommittee S. S. Heart Disease and Stroke Statistics-2016 Update: A ReportFrom the American Heart Association // Circulation. ‒ 2016.
‒ T. 133, № 4. ‒ C. e38360.116. Nakayama M., Metoki H., Terawaki H., Ohkubo T., Kikuya M., Sato T., NakayamaK., Asayama K., Inoue R., Hashimoto J., Totsune K., Hoshi H., Ito S., Imai Y. Kidneydysfunction as a risk factor for first symptomatic stroke events in a general Japanesepopulation--the Ohasama study // Nephrol Dial Transplant. ‒ 2007. ‒ T. 22, № 7. ‒ C.1910-5.117.
Nelson S. E., Shroff G. R., Li S., Herzog C. A. Impact of chronic kidney disease onrisk of incident atrial fibrillation and subsequent survival in medicare patients // J AmHeart Assoc. ‒ 2012. ‒ T. 1, № 4. ‒ C. e002097.118. Ng K. P., Edwards N. C., Lip G. Y., Townend J. N., Ferro C.
J. Atrial fibrillation inCKD: balancing the risks and benefits of anticoagulation // Am J Kidney Dis. ‒ 2013. ‒T. 62, № 3. ‒ C. 615-32.119. Oldgren J., Healey J. S., Ezekowitz M., Commerford P., Avezum A., Pais P., ZhuJ., Jansky P., Sigamani A., Morillo C. A., Liu L., Damasceno A., Grinvalds A., NakamyaJ., Reilly P. A., Keltai K., Van Gelder I. C., Yusufali A. H., Watanabe E., Wallentin L.,Connolly S.
J., Yusuf S., Investigators R.-L. A. F. R. Variations in cause and managementof atrial fibrillation in a prospective registry of 15,400 emergency department patients in46 countries: the RE-LY Atrial Fibrillation Registry // Circulation. ‒ 2014. ‒ T. 129, №15. ‒ C. 1568-76.127120. Olesen J. B., Lip G. Y., Kamper A. L., Hommel K., Køber L., Lane D. A.,Lindhardsen J., Gislason G. H., Torp-Pedersen C.
Stroke and bleeding in atrial fibrillationwith chronic kidney disease // N Engl J Med. ‒ 2012. ‒ T. 367, № 7. ‒ C. 625-35.121. Patel M. R., Mahaffey K. W., Garg J., Pan G., Singer D. E., Hacke W., BreithardtG., Halperin J. L., Hankey G. J., Piccini J. P., Becker R. C., Nessel C. C., Paolini J. F.,Berkowitz S. D., Fox K. A., Califf R. M., Investigators R.
A. Rivaroxaban versus warfarinin nonvalvular atrial fibrillation // N Engl J Med. ‒ 2011. ‒ T. 365, № 10. ‒ C. 883-91.122. Pathak R., Pandit A., Karmacharya P., Aryal M. R., Ghimire S., Poudel D. R.,Shamoun F. E. Meta-analysis on risk of bleeding with apixaban in patients with renalimpairment // Am J Cardiol. ‒ 2015. ‒ T. 115, № 3. ‒ C. 323-7.123. Pengo V., Crippa L., Falanga A., Finazzi G., Marongiu F., Moia M., Palareti G., PoliD., Testa S., Tiraferri E., Tosetto A., Tripodi A., Siragusa S., Manotti C.
Phase III studieson novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond theexcellent results // J Thromb Haemost. ‒ 2012. ‒ T. 10, № 10. ‒ C. 1979-87.124. Piccini J. P., Stevens S. R., Chang Y., Singer D. E., Lokhnygina Y., Go A. S., PatelM. R., Mahaffey K. W., Halperin J. L., Breithardt G., Hankey G. J., Hacke W., BeckerR. C., Nessel C. C., Fox K.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
